iBio (NASDAQ:IBIO) Rating Lowered to Sell at Wall Street Zen

iBio (NASDAQ:IBIO) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued to investors on Saturday.

A number of other research analysts also recently issued reports on IBIO. Leerink Partners upgraded iBio to a “strong-buy” rating in a report on Friday, October 17th. Weiss Ratings reissued a “sell (d-)” rating on shares of iBio in a research note on Monday, December 29th. Finally, Lifesci Capital raised iBio to a “strong-buy” rating in a research note on Thursday, December 18th. Two research analysts have rated the stock with a Strong Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Buy”.

iBio Trading Up 5.2%

Shares of NASDAQ IBIO opened at $2.22 on Friday. The business has a fifty day moving average price of $2.15. iBio has a 52 week low of $0.56 and a 52 week high of $6.89. The stock has a market capitalization of $76.68 million, a P/E ratio of -2.22 and a beta of 1.26.

iBio (NASDAQ:IBIO) last announced its quarterly earnings results on Tuesday, February 10th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.01).

iBio Company Profile

iBio, Inc, a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever.